The Government recently granted conditional approval for Qdenga, the first dengue vaccine to be approved for use in Malaysia. This comes in the wake of an alarming 86% surge in dengue cases last year— with 100 fatalities reported— underscoring an urgent public health challenge. With a national goal of zero dengue-related deaths by 2030, how will the introduction of Qdenga shape Malaysia’s battle against this relentless disease? On this episode of #ConsiderThis Melisa Idris speaks to Vanessa Daniel, Acting Director of the Southeast Asia Regional Office for the Drugs for Neglected Diseases Initiative (DNDi) which is a non-profit which seeks to ensure treatment for neglected diseases are available, affordable, and adapted to the communities who need them.